Skip to main content
. Author manuscript; available in PMC: 2011 Jun 1.
Published in final edited form as: Curr Pharm Des. 2010 Jun;16(16):1843–1862. doi: 10.2174/138161210791209027

Table 1.

PTP inhibitors that have been evaluated in vivo

Inhibitor PTP Animal Studies Human Trials Firm Reference
BN82002
Cmp 26*		 Cdc25 Inhibit Mia PaCa-2 pancreatic tumor
xenograft growth.		 IPSEN [156]
BN82685
Cmp 27 		Cdc25 Inhibit Mia PaCa-2 pancreatic tumor
xenograft growth.		 IPSEN [157]
IRC-083864
Debio-0931
Cmp 25 		Cdc25 Inhibit Mia PaCa-2 pancreatic tumor and
LNCaP prostate tumor xenograft growth.		 Phase I (planned) IPSEN/
Debiopharm		 [155]
Cmp 17 PTP1B Lower blood glucose level.
Delay onset of ErbB2-induced mammary
tumor.		 Merck Frosst [102]
Ertiprotafib
Cmp 18 		PTP1B Lower fasting blood glucose and insulin.
Improve glycemic excursion.
Improve lipid profiles.		 Phase II in type II
diabetes
(Discontinued
because of
insufficient efficacy
and concerns about
side-effects due to
inhibition of other
targets)		 Wyeth
Research		 [107]
MSI-1436
Trodusquemine
Cmp 19 		PTP1B Suppress appetite
Induce fat-specific weight loss
Improve insulin and leptin levels		 Phase I Genaera [108]
Cmp 13 Glepp1 Inhibit thioglycolate-induced peritonitis.
Inhibit dermatitis.
Inhibit ulcerative colitis.		 Merck
Serono		 [90]

Cmp: compound